Hypogonadotropism Clinical Trial
— TRANSFERENCEOfficial title:
A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen™ TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects
| Verified date | January 2024 |
| Source | Transdermal Delivery Solutions Corp |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.
| Status | Enrolling by invitation |
| Enrollment | 96 |
| Est. completion date | December 2024 |
| Est. primary completion date | October 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: 1. Healthy Volunteers 2. Subject Couples, between 18 and 80 years of age, inclusive. 3. The subject couple is willing and able to read, understand the Subject Information Sheets and provide written informed consent. 4. The subject has a body mass index (BMI) within 18-30 kg/m2. 5. The subject is in otherwise good health as determined by medical history and physical examination. 6. Female subjects must be practicing an acceptable method of birth control. Acceptable methods of birth control include hormonal contraceptives. If practicing an acceptable method of birth control, a negative urine pregnancy test result has been obtained on each Treatment Day. 7. The subject is a non-smoker. 8. The female subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments. 9. The subject couple is willing and able to comply with all testing and requirements defined in the protocol. 10. The subject couple is willing and able to return to the study site for all visits. Exclusion Criteria: 1. The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading or positive pregnancy test. 2. The subject has had a clinically significant illness within 30 days preceding entry into this study. 3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease. 4. The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds. 5. The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication (excluding oral contraceptives). 6. The subject has donated or lost a significant volume of blood (>450mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal. 7. The subject has a history of substance abuse or a current positive urine drug screen. 8. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males, and 14 for females). 9. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry. 10. Pregnancy |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Transdermal Delivery Solutions Corp | Advanced Therapies Centre, The London Clinic |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Transference of Topical Testosterone from Dosed Males with application area covered to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Maximum Serum Concentration or Cmax | Determination of whether testosterone from the Testagen® preparation is transferable from the skin of the patient with application area covered to his partner and therefore detectable in the blood of female partner and if so, how much as measured by ELISA method as applied to blood samples and computed for Concentration Max (Cmax) and Area Under the Curve (AUC) for 24 hours post dose measured in ng/dL Testosterone as determined by ELISA method. | 30 minutes to 24 hours post dose | |
| Other | Transference of Topical Testosterone from Dosed Males with application area covered to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Area Under the Curve or AUC | Determination of whether testosterone from the Testagen® preparation is transferable from the skin of the patient and therefore detectable in the blood of the female partner with application area covered to his partner and if so, how much as measured by ELISA method as applied to blood samples and computed Area Under the Curve (AUC) for 24 hours post dose measured in ng/dL Testosterone as determined by ELISA method. | 30 minutes to 24 hours post dose | |
| Primary | Transference of Topical Testosterone from Dosed Males to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Maximum Serum Concentration or Cmax. | Determination of whether testosterone from the Testagen® preparation is transferable from the skin of the patient to his partner and therefore detectable in the blood of female partner and if so, how much as measured by ELISA method as applied to blood samples and computed for Concentration Max (Cmax) for 24 hours post dose measured in ng/dL Testosterone as determined by ELISA method. | 30 minutes to 24 hours post dose | |
| Secondary | Transference of Topical Testosterone from Dosed Males to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Area Under Curve or AUC. | Determination of whether testosterone from the Testagen® preparation is transferable from the skin of the patient to his partner and therefore detectable in the blood of female partner and if so, how much as measured by ELISA method as applied to blood samples and computed for Area Under the Curve (AUC) for 24 hours post dose measured in ng/dL Testosterone as determined by ELISA method. | 30 minutes to 24 hours post dose |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT01894308 -
A Dose Ranging Study to Examine TDS-Testosterone 5%
|
Phase 2 |